It has been reported that FGFR1 amplifications emerge in various of cancers, such as NSCLC (12%–17%), prostate cancer (16%), myxofibrosarcoma (20%), bladder cancer (9%), esophageal cancer (9%), colorectal cancer (6%), and in undifferentiated pleomorphic sarcomas (7%).3, 4. This evidence concerns the gene FGFR1 and Familial prostate cancer.